NDAORALTABLET
Approved
Jan 2013
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
2
Data completeness
5/8 — Partial
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KAZANO is a fixed-dose oral combination tablet containing alogliptin (a DPP-4 inhibitor) and metformin hydrochloride for the treatment of type 2 diabetes mellitus. The alogliptin component enhances incretin-mediated glucose-dependent insulin secretion and suppresses glucagon secretion, while metformin reduces hepatic glucose production and improves insulin sensitivity. This adjunct therapy is indicated for patients inadequately controlled on metformin monotherapy or those switching from separate component pills.
$0.112MPart D
LOE ApproachingDeclining
2.7 years to LOEDeclining Part D claims and minimal spending signal a contracting market with reduced commercial team expansion and focus shifting to LOE mitigation strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age"
Started Feb 2017
1,026 enrolled
Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan
Started Jan 2007
480 enrolled
Diabetes Mellitus, Type 2
Why This Matters for Your Career
Worked on KAZANO at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.